What are the more promising employment directions in the pharmaceutical industry?

At the end of 20 13, 10, the first biomedical professional investment fund led by government agencies was formally established recently, and it will invest 260 million yuan in two years to devote itself to the transformation of the early achievements of the biomedical industry and the incubation of enterprises.

In recent years, biopharmaceutical industry has been the focus of global pharmaceutical development, especially the application of genetic engineering, cell engineering, enzyme engineering and fermentation engineering in pharmaceutical industry, which greatly promoted the development of pharmaceutical industry. With its good clinical application, biopharmaceutical industry has become a new industry with strong vitality and growth in China. However, the lack of technological innovation capacity has seriously restricted the development of China's biopharmaceutical industry.

There are many reasons for the lack of innovation ability of biopharmaceutical industry in China, but it is undeniable that the lack of R&D investment is one of the main reasons for the backward technological innovation ability. From a global perspective, the world's most famous biopharmaceutical companies, such as Novartis, Roche, Merck, etc. , its annual R&D investment accounts for a high proportion of its operating income. The figure below shows the top 20 companies in the global biopharmaceutical industry in 20 12 years. It can be seen that, except Tiwa and Baxter, they all exceeded 1 1%.

According to the data in the Report on Market Demand Forecast and Investment Strategic Planning of Biopharmaceutical Industry released by Prospective Industry Research Institute, among the leading biopharmaceutical enterprises in China, except for Watson's R&D investment in Yunnan in 2065,438+02, the R&D investment of other enterprises is still low.

I hope it works for you. Please ask questions if you don't understand. Thank you.